Quick Answer
Tenaya Therapeutics, Inc. reported Net Income of -$90.60 million for fiscal year 2025.
Tenaya Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$90.60M +18.5% |
-$111.13M +10.4% |
-$124.08M -0.3% |
-$123.67M -70.1% |
-$72.72M -89.4% |
-$38.40M |
| Diluted EPS | -$0.59 +55.0% |
-$1.31 +22.0% |
-$1.68 +39.1% |
-$2.76 +32.7% |
-$4.10 | — |
| Total Assets | $146.92M +22.5% |
$119.94M -29.7% |
$170.51M -38.9% |
$278.94M -11.2% |
$314.19M +112.1% |
$148.16M |
| Cash and Equivalents | $100.55M +2225.9% |
$4.32M -90.5% |
$45.68M -52.1% |
$95.27M +149.9% |
$38.13M -70.3% |
$128.53M |
| Stockholders Equity | $123.27M +32.8% |
$92.85M -33.4% |
$139.42M -42.7% |
$243.38M -12.6% |
$278.53M +442.5% |
-$81.31M -85.9% |
| R&D Expense | $68.61M -20.9% |
$86.74M -11.5% |
$98.04M +3.7% |
$94.54M +73.8% |
$54.39M +74.9% |
$31.10M |
| Operating Income | -$93.33M +19.5% |
-$115.95M +11.6% |
-$131.19M -4.4% |
-$125.62M -72.5% |
-$72.81M -87.1% |
-$38.91M |
| Shares Outstanding | 216.76M +150.5% |
86.54M +26.7% |
68.33M +2.2% |
66.86M +61.9% |
41.29M +3311.6% |
1.21M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$20.27M | +20.9% | +12.9% |
| Diluted EPS | September 30, 2025 | -$0.12 | +60.0% | +14.3% |
| Total Assets | September 30, 2025 | $104.98M | -25.3% | -14.1% |
| Cash and Equivalents | September 30, 2025 | $56.31M | +584.1% | -10.1% |
| Stockholders Equity | September 30, 2025 | $82.87M | -26.4% | -17.0% |
| R&D Expense | September 30, 2025 | $15.36M | -24.5% | -11.6% |
| Operating Income | September 30, 2025 | -$20.94M | +21.6% | +13.1% |
- Tenaya Therapeutics, Inc. reported Net Income of -$90.60 million for fiscal year 2025.
- Tenaya Therapeutics, Inc. showed an increase of +18.5% in Net Income compared to the prior fiscal year.
- Tenaya Therapeutics, Inc. reported Diluted EPS of $0.59 per share (loss) for fiscal year 2025.
- Tenaya Therapeutics, Inc. showed an increase of +55.0% in Diluted EPS compared to the prior fiscal year.
- Tenaya Therapeutics, Inc. reported Total Assets of $146.92 million for fiscal year 2025.
- Tenaya Therapeutics, Inc. showed an increase of +22.5% in Total Assets compared to the prior fiscal year.
- Tenaya Therapeutics, Inc. reported Cash and Equivalents of $100.55 million for fiscal year 2025.
- Tenaya Therapeutics, Inc. showed an increase of +2225.9% in Cash and Equivalents compared to the prior fiscal year.
- Tenaya Therapeutics, Inc. reported Stockholders Equity of $123.27 million for fiscal year 2025.
- Tenaya Therapeutics, Inc. showed an increase of +32.8% in Stockholders Equity compared to the prior fiscal year.
- Tenaya Therapeutics, Inc. reported R&D Expense of $68.61 million for fiscal year 2025.
- Tenaya Therapeutics, Inc. showed a decrease of -20.9% in R&D Expense compared to the prior fiscal year.
- Tenaya Therapeutics, Inc. reported Operating Income of -$93.33 million for fiscal year 2025.
- Tenaya Therapeutics, Inc. showed an increase of +19.5% in Operating Income compared to the prior fiscal year.
- Tenaya Therapeutics, Inc. reported Shares Outstanding of 216.76 million shares for fiscal year 2025.
- Tenaya Therapeutics, Inc. showed an increase of +150.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: